GMDA Live signaler | Maksimer profitt med Getagraph.com

SELG 118870 min ago

@ $0.367

Utstedt: 13 feb 2024 @ 22:00

Avkastning: -91.09%

Forrige signal: feb 13 - 20:29

Forrige signal: Kjøp

Avkastning: 0.55 %

Live Chart Being Loaded With Signals

Commentary (5 apr 2024 @ 22:00):

Stats
Dagens volum	23.04M
Gjennomsnittsvolum	9.67M
Markedsverdi	4.34M
EPS	$0 ( 2024-03-27 )
Neste inntjeningsdato	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-31	Moch Kenneth I	Buy	200 000	Ordinary Shares
2024-01-31	Wills Stephen T	Buy	200 000	Ordinary Shares
2024-01-31	Tomasello Shawn	Buy	200 000	Ordinary Shares
2024-01-31	Adams Julian	Buy	200 000	Ordinary Shares
2024-01-31	Simantov Ronit	Buy	480 319	Ordinary Shares

INSIDER POWER
94.97
Last 90 transactions
Buy: 8 073 627 \| Sell: 418 674

Volum Korrelasjon

Lang: 0.12 (neutral)

Kort: 0.82 (strong)

Signal:(73.984) Same movement expected

Gamida Cell Ltd Korrelasjon

10 Mest positive korrelasjoner
AMRS	0.906
ATHN	0.891
BRZE	0.89
PRFT	0.882
EZGO	0.88
PTRA	0.878
ARIZ	0.873
SHCR	0.87
GSHD	0.87
LULU	0.87

10 Mest negative korrelasjoner
LABP	-0.944
LWAY	-0.934
IDN	-0.928
SCTL	-0.923
NN	-0.915
MESO	-0.914
CURI	-0.91
VFF	-0.908
ALR	-0.907
MOTNU	-0.906

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Gamida Cell Ltd Korrelasjon - Valuta/Råvare

0.00
( neutral )

Gamida Cell Ltd Økonomi

Annual	2023
Omsetning:	$1.78M
Bruttogevinst:	$-1.69M (-94.96 %)
EPS:	$-0.570

FY	2023
Omsetning:	$1.78M
Bruttogevinst:	$-1.69M (-94.96 %)
EPS:	$-0.570

FY	2022
Omsetning:	$0
Bruttogevinst:	$-440 000 (0.00 %)
EPS:	$-2.42

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Gamida Cell Ltd

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.